By R. Jesper. Brigham Young University Idaho.
Proponents cite a plethora of self- Motor skills and reaction time are also altered purchase propecia 5mg mastercard, so skilled reports regarding the effectiveness of medical marijuana for activity of various kinds is frequently disrupted buy propecia 1mg with visa. Peripher- a wide range of disorders generic 1 mg propecia with visa, whereas opponents question its ally, marijuana produces prominent effects on the cardiovas- efficacy and point to potential deleterious effects of smoked cular system characterized by tachycardia, and at high doses marijuana. The scientific rationale for deciding the fate of it can produce orthostatic hypotension. There are several marijuana as a therapeutic agent is often ignored. However, THC has provided most of the evidence for can- Billy R. Dewey: Department of Pharmacology nabinoid effects in laboratory animals. As for chronic mari- and Toxicology, Virginia Commonwealth University, Richmond, Virginia. Vincenzo DiMarzo: Istituto per la Chimica di Molecole Di Interesse juana use in humans, concerns arise because of potential Biologico, Consiglio Nazionale delle Ricerche, Naples, Italy. There has been considerable been proposed that chronic marijuana use in adolescents interest in cannabinoid effects on performance, cognition, may result in long-term memory impairment (6). There are and the development of dependence, discussed in the fol- also indications that persons with learning disabilities may lowing sections. Almost all stud- ies have shown that marijuana has no effect on retrieval of already-learned material. THC reliably alters the perception Performance of time, with subjects overestimating elapsed time or experi- Cannabinoids affect sensory, psychomotor, and cognitive encing an increase in the subjective rate of time (2). Evi- function and the ability to perform certain tasks. There dence has emerged from several studies that chronic mari- is little dispute that high doses of marijuana can disrupt juana use after many years produces subtle cognitive performance when the task is difficult. As may be expected, changes, specifically with regard to attention, as well as orga- the effects of marijuana on performance become more vari- nization and integration of complex information (8). In a comprehensive review, Chait binoid-induced deficits in several animal models. The natu- and Pierri concluded that marijuana, at doses that produce rally occurring cannabinoids as well as a wide range of syn- moderate levels of intoxication, can affect a wide range of thetic compounds have been demonstrated to impair learned and unlearned behaviors, including simple motor learning and memory in numerous laboratory animal mem- tasks, and more complex psychomotor and cognitive tasks ory tasks. Cannabinoid-induced impairment of flying and driving cannabinoids impaired spatial memory in rats, as assessed has been documented in numerous studies, although inter- by the eight-arm radial maze, and retarded completion time pretation of the results remains controversial. Direct injection of cannabinoids into the hippocampus quently found in the blood of drivers involved in automo- impaired memory, and this appeared specific to cognition bile accidents, and marijuana use has been associated with because no other pharmacologic effects were produced (10). One study compared the effects of marijuana on equilib- Tolerance and Dependence rium and simulated driving (3). Marijuana smoking that produced a 'high' also increased body sway and increased There is convincing evidence for the development of toler- brake latency to a degree comparable to that found in per- ance to THC in humans (11). Tolerance developed to a sons with breath alcohol concentrations near 0. Although robust acute effects of nomic functions, increases in intraocular pressure, sleep dis- marijuana were found on subjective and physiologic mea- turbances, and mood changes (11). High doses of 9-THC sures, and on smooth-pursuit eye tracking performance, no were required for a sustained period of time to achieve be- 9 effects were evident the day after administration, a finding havioral tolerance. If the doses of -THC were sufficiently indicating that the residual effects of smoking a single mari- small and infrequent, little behavioral tolerance seemed to juana cigarette are minimal. Several early reports came from countries where potent marijuana was used for long periods of time. Cognition On deprivation of marijuana, users experienced auditory 9 There is lack of consensus regarding the effects of -THC and visual hallucinations and irritability. The development on memory and learning in that results are often inconsis- of tolerance and dependence has been studied under rigor- tent and test specific (2,6). In one study, high cal observations and cross-cultural studies that chronic mari- doses of marijuana extract or 9-THC were administered juana use does not appear to produce severe gross for up to 21 days, and the most prominent subjective symp- impairment, but rather it may produce subtle cognitive defi- toms were increased irritability and restlessness. The most frequently mentioned deficits were slower symptoms included insomnia, anorexia, increased sweating, psychomotor performance, poorer perceptual motor coordi- and mild nausea, although they were variable. During the past few years, symptoms were increased body temperature, weight loss, greater attention has been directed toward investigating spe- and hand tremor. Readministration of a marijuana cigarette cific cognitive deficits and relating these effects directly to or oral 9-THC alleviated the objective and subjective ef- marijuana use. Whereas THC appears to produce its great- fects, a finding suggesting the establishment of a withdrawal est decrement in free recall or short-term memory, it has symptom. Similar findings were reported by Georgotas and Chapter 106: Marijuana 1521 Zeidenberg in abstinent subjects who had smoked high More recently, Budney et al. One study juana users seeking treatment for marijuana dependence had (14) found that lower doses of THC (80 and 120 mg/day, experienced symptoms consistent with either moderate or orally, each for 4 days) initially produced ratings of 'high,' severe dependence (23). These investigators also reported increased food intake over baseline by 35% to 45%, and that marijuana-dependent persons exhibit substantial prob- decreased verbal interaction among participants (14). Comparison of marijuana- and cocaine-depen- ance developed to the subjective effects of THC but not to dent patients revealed comparable substance-use histories its effects on food intake or social behavior. Abstinence from and a range of impairments in both groups. However, the THC produced anxious, depressed, and irritable symptoms, marijuana-dependent patients showed less severe depen- decreased the quantity and quality of sleep, and decreased dence. The marijuana group was more ambivalent and less food intake (14). A similar study conducted with marijuana confident about stopping their marijuana use than the co- cigarettes resulted in similar effects and led to the conclusion caine group was about stopping their cocaine use. The au- that abstinence symptoms may play a role in maintaining thors concluded that treatment-seeking, marijuana-depen- daily marijuana use, even at levels of use that do not produce dent persons exhibit substantial problems and urged tolerance (15). There are numerous cases in which Some predisposing factors may contribute to marijuana persons seek treatment for dependence of which marijuana dependence in some persons. These patients typically com- juveniles diagnosed with both substance abuse and conduct plained of being unable to stop or to decrease their mari- disorders have serious problems related to cannabis, and juana use despite experiencing sleepiness, depression, inabil- most met standard adult criteria for cannabis dependence ity to concentrate, and memorization difficulties that they (25). Two-thirds of these cannabis-dependent patients re- directly attributed to marijuana exposure. The data indicate that for adolescents ies reported similar problems in daily users of marijuana with conduct problems, cannabis use is not benign. Several groups of investigators have used DSM-III-R risk factors may also contribute. With regard to prevalence of marijuana abuse and use, abuse, and dependence as defined by DSM-IV criteria dependence, the strongest evidence was provided by the (26). These investigators concluded that in women, genetic Epidemiological Catchment Area study involving 20,000 risk factors have a moderate impact on the probability of persons in five geographic areas of the United States (21).
Much of the direct work of delivering therapy to a child is carried out by parents and school staff generic propecia 1mg with amex. Increasingly purchase propecia 5mg otc, therapists assume a consultative role and their skills in this regard are buy propecia 1mg amex, therefore, critical. Existing frameworks for understanding complex non-pharmacological interventions offer a useful structure by which this complexity can be understood. Related to this, understandings of mechanisms of change are limited. Parents and professionals strongly identified participation as one of the overarching objectives of therapy interventions. In addition, as a concept or intervention objective, it may not be explicitly operationalised in practice. Furthermore, the notion of participation as an appropriate and meaningful outcome indicator for therapy interventions was questioned, particularly with respect to, for example, evaluations of a specific procedure. There was agreement that, when properly implemented into a study design, it may be an appropriate indicator in studies evaluating the impact of wider models of care. Some of these outcomes may be better conceived as intermediate outcomes. Quality of life, physical and emotional well-being, resilience and self-management were identified as other potentially relevant higher-level outcomes. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals xxv provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. SCIENTIFIC SUMMARY Children with non-progressive neurodisability are a highly heterogeneous population. Many have complex needs and require the support and care of a number of professionals and services. The neurological origins of their impairments mean that children with predominantly physical/motor impairments – specified as the population in question for this scoping study – may well have cognitive impairment. For some types of research, additional or alternative approaches to defining populations, for example in terms of gross motor function or desired goals, may be more meaningful and appropriate. Typically, there is not a strong culture of research within therapy services; however, within the professions there is growing engagement with and interest in research. A broad-ranging agenda of research priorities was identified. A number of methodological and study design issues were identified as barriers to evaluation research. Research priorities concerning particular techniques, procedures or items of equipment generated a long list of potential studies. These appeared to be located in personal preferences and clinical experience, and none emerged as receiving strong and consistent support. There was universal consensus that evaluative research needs to use mixed methods, and that patient experience as well as outcomes should be captured. Health economics and implementation science were consistently identified as needing to be core components of evaluation studies. Conclusions The purpose of this study was to provide a description of current thinking, practices and models of service delivery with respect to physiotherapy, occupational therapy and speech and language therapy. It sought to consult with relevant health professionals, parents and children and young people. In terms of the aspect of the study that sought to explore research priorities, the absence of children and young people in the study represents a significant limitation. However, a broad representation of health professionals and parents was achieved, response rates were very high and study participants were highly engaged. The context of therapy provision has been described, including shifts and developments in thinking and practice across the professions. These have been influenced by new models of disability and impairment and adopting notions of family-focused and goals-focused care, as well as significant changes in the level of investment in therapy provision. In terms of evaluative research, there was a strong call for studies that tested and informed developments in practice and ways of working and/or models of service delivery. No particular techniques or procedures emerged as clear research priorities, although sometimes techniques not currently available within NHS provision were identified. For some, research into the effectiveness, or impact, of specific techniques and equipment was seen as secondary to, or irrelevant compared with, research into models of care and ways of working. Funding Funding for this study was provided by the Health Technology Assessment programme of the NIHR. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals xxvii provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Indeed, as we have highlighted in bold, this topic constituted 4 of those 10 areas. The following overarching research question was generated from this process: what therapy interventions are, could and should be offered to children with neurodisability to help improve participation outcomes? BOX 1 Top 10 research questions agreed as shared priorities1 1. What is the appropriate age of onset/strategies/dosage/direction of therapy interventions? To improve communication for children and young people with neurodisability, (a) what is the best way to select the most appropriate communication strategies? And (b) how to encourage staff/carers to use these strategies to enable communication? Does the appropriate provision of wheelchairs to enable independent mobility for very young children improve their self-efficacy? What is the (long-term) comparative safety and effectiveness of medical and surgical spasticity management techniques (botulinum neurotoxin A, selective dorsal rhizotomy, intrathecal baclofen, orally administered medicines) in children and young people with neurodisability? Does a structured training programme, medicines and/or surgery speed up the achievement of continence (either/or faecal or urinary) for children and young people with neurodisability? What strategies are effective to improve engagement in physical activity (to improve fitness, reduce obesity, etc. What is the long-term safety, effectiveness and sustainability of behavioural strategies and/or drugs (e. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 1 provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
M em brane technology is also evolving cheap propecia 1 mg on-line, and antithrom bogenic m em branes are on the horizon effective 1mg propecia. Finally the application of these therapies is likely to expand to other arenas order propecia 5mg otc, including the treatm ent of sepsis, congestive heart failure, and m ulti- organ failure. An exciting area of innovative research is the developm ent of a bioartificial tubule utilizing porcine tubular epithelial cells grown in a hollow fiber to add tubular function to the filtrative function pro- vided by dialysis. These devices are likely to be utilized in com bination with CRRT to truly provide com - plete RRT in the near future. M ehta RL: Therapeutic alternatives to renal replacem ent therapy for 10. M ehta RL, M cDonald BR, Aguilar M M , W ard DM : Regional citrate 2. Shapiro W B: The current status of Sorbent hem odialysis. Sem in D ial anticoagulation for continuous arteriovenous hem odialysis in critically 1990, 3:40–45. Steiner RW : Continuous equilibration peritoneal dialysis in acute renal 13. Kroh UF, H oll TJ, Steinhausser W : M anagem ent of drug dosing in failure. Bellom o R, Ronco C, M ehta RL: N om enclature for continuous renal 14. M onson P, M ehta RL: N utritional considerations in continuous renal replacem ent therapies. H enderson LW : H em ofiltration: From the origin to the new wave. Golper TA: Indications, technical considerations, and strategies for J Kidney D is 1996, 28(5)S3:100–104. M ehta RL: Renal replacem ent therapy for acute renal failure: M ed 1992, 7:310–317. M ehta RL: Fluid m anagem ent in continuous renal replacem ent thera- 8. Lindhout T: Biocom patability of extracorporeal blood treatm ent. Palevsky PM : Continuous renal replacem ent therapy com ponent selec- 9(Suppl. W ard RA: Effects of hem odialysis on corpulation and platelets: Are 18. N ephrol D ial Transplant bicarbonate buffered haem ofiltration fluids: Use in critically ill 1995, 10(Suppl. Golper TA: Continuous arteriovenous hem ofiltration in acute renal 33. Alarabi AA, Danielson BG, W ikstrom B, W ahlberg J: O utcom e of failure. Kierdorf H : Continuous versus interm ittent treatm ent: clinical results M ed Sci 1989, 94:299–303. M cDonald BR, M ehta RL: Decreased m ortality in patients with acute 21. Lauer renal failure undergoing continuous arteriovenous hem odialysis. Paganini EP: Slow continuous hem ofiltration and slow continuous ultrafiltration. Conventional dialysis versus acute continuous hem odiafil- 23. Schrier RW , Abraham H J: Strategies in m anagem ent of acute renal failure in the intensive therapy unit. Care: Acute Renal Failure in the Intensive Therapy Unit. Bellom o R, Boyce N : Continuous venovenous hem odiafiltration com - Bihari D, N eild G. Kruczynski K, Irvine-Bird K, Toffelm ire EB, M orton AR: A com pari- M etabolic control and outcom es in sixty patients. N ephron 1995, son of continuous arteriovenous hem ofiltration and interm ittent 70:185–196. Sim pson K, Allison M EM : Dialysis and acute renal failure: can m or- patients with acute renal failure. Kierdorf H : Einfuss der kontinuierlichen H am ofiltration auf 26. W ilkins RG, Faragher EB: Acute renal failure in an intensive care unit: Proteinkatabolism us, M ediatorsubstanzen und Prognose des akuten Incidence, prediction and outcom e. N ierenversagens [H abilitation-Thesis], M edical Faculty Technical 27. Firth JD: Renal replacem ent therapy on the intensive care unit. Yang VC, Fu Y, Kim JS: A potential throm bogenic hem odialysis m em - 29. Kierdorf H : Continuous versus interm ittent treatm ent: Clinical results branes with im paired blood com patibility. Jakob SM , Frey FJ, Uhlinger DE: Does continuous renal replacem ent 42. N ephrol D ial filtration for the treatm ent of congestive heart failure. M ehta RL: Acute renal failure in the intensive care unit: W hich out- 43. Drum l W : Prophylactic use of continuous renal replacem ent therapies com es should we m easure? H um es H D, M ackay SM , Funke AJ, Buffington DA: The bioartificial nous hem ofiltration. Anasth Intensivther N otfallm ed 1986, renal tuble assist device to enhance CRRT in acute renal failure. De Broe he kidneys are susceptible to toxic or ischemic injury for sever- al reasons. Thus, it is not surprising that an impressive list of Texogenous drugs and chemicals can cause clinical acute renal failure (ARF). On the contrary, the contribution of environmental toxins to ARF is rather limited. In this chapter, some of the most com- mon drugs and exogenous toxins encountered by the nephrologist in clinical practice are discussed in detail. The clinical expression of the nephrotoxicity of drugs and chemi- cals is highly variable and is influenced by several factors. Among these is the direct toxic effect of drugs and chemicals on a particular type of nephron cell, the pharmacologic activity of some substances and their effects on renal function, the high metabolic activity (ie, vul- nerability) of particular segments of the nephron, the multiple trans- port systems, which can result in intracellular accumulation of drugs and chemicals, and the high intratubule concentrations with possible precipitation and crystallization of particular drugs.
...or by Phone or Mail
PO Box 800
Buffalo, NY 14231 USA
Toll free 1-800-825-2675
Hours 8:30 am 5:00 pm EST M-F